



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/823,468

04/12/2004

Sanford D. Altman

OAV-103XC1

4577

23557 7590 12/18/2008  
SALIWANCHIK LLOYD & SALIWANCHIK  
A PROFESSIONAL ASSOCIATION  
PO BOX 142950  
GAINESVILLE, FL 32614-2950

EXAMINER

DEAK, LESLIE R

ART UNIT

PAPER NUMBER

3761

MAIL DATE

DELIVERY MODE

12/18/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/823,468	<b>Applicant(s)</b> ALTMAN, SANFORD D.	
	<b>Examiner</b> LESLIE R. DEAK	<b>Art Unit</b> 3761	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 22 September 2008.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,3-7,11-16,24-28 and 31-35 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-7,11-16,24-28 and 31-35 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 25 January 2007 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

## DETAILED ACTION

### ***Claim Rejections - 35 USC § 103***

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1, 3-7, 11-16, 24, 25, 31, and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Us 4,385,631 to Uthmann.

In the specification and figures, Uthmann discloses the apparatus substantially as claimed by Applicant.

With regard to claim 1, Uthmann discloses a dual-lumen catheter with a first arterial, interior catheter 11 with distal end 20, a second, venous, outer catheter 12, both of which are attached to a hollow hub or cap 14 (see FIG 1 and accompanying text). The two lumens are coaxial along their entire length to hub or cap 14. (Applicant illustrates that FIGS 1A and 1B of the instant specification illustrate a coaxial configuration. In FIG 1B, the inner catheter is offset from the center of the outer catheter. Since the catheters still share some of the same axis, this configuration is interpreted by the Examiner to encompass the coaxial configuration claimed by Applicant. Furthermore, Applicant illustrates that the lumens are coaxial to the hub 40 in FIG 2B. Accordingly, it is the position of the Examiner that the lumens disclosed by Uthmann are coaxial along the entire length as illustrated by Applicant.) The arterial lumen's distal tip 20 may extend beyond the distal end of venous catheter 12 (see FIG

1). Both lumens are slideable within the cap 14 and may be removed without altering the structure of either tube (see column 2, lines 48-67). Uthmann discloses that both the venous and arterial lumens have a plurality of distal openings. However, it has been held that the omission of an element (such as an opening) and its function is obvious if the function of the removed element is not desired. See MPEP § 2144.04(II)(A). Since Applicant does not desire the function of multiple holes, it would have been obvious to one having ordinary skill in the art at the time of invention to eliminate the undesired holes from the apparatus disclosed by the cited prior art.

With regard to claims 3-5 and 12-14, Uthmann is silent as to the distance between the distal end of the inner lumen and the distal end of the outer lumen. However, Uthmann clearly discloses that the inner lumen 11 is slideable within the outer lumen 12 (see column 1, lines 58-67). As such, Uthmann discloses that the disclosed catheter is capable of being deployed with variable distances between the inner and outer tips. It has been held that where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP § 2144.05 (II)(A). In the instant case, Uthmann discloses that the distance between the tips may be adjusted to minimize pendulum blood flow (see column 1, lines 40-55). By varying the distance between the distal ends, a change in pendulum blood flow results. Accordingly, it is the position of the Examiner that the distance between the distal ends, which is adjustable, as taught by Uthmann, is a result-effective variable, the optimization of which is not patentable over the cited prior art.

With regard to claims 6, 7, 15, 16 Uthmann discloses that the distal end of the venous or outer lumen is tapered at 18 and the tip of the arterial or inner catheter 11 comprises a conical, or tapered tip (see FIGS 1, 2, column 2, lines 64-68).

With regard to claim 11, Uthmann illustrates that the inner catheter 11 lays against the wall of outer catheter 12, creating a circle-c configuration (see FIG 1).

With regard to claims 24 and 25, Uthmann illustrates that the venous or outer lumen comprises at least two apertures 19, which are illustrated as having an oval shape.

With regard to claims 31 and 33, Uthmann disclose that an incision is made into a blood vessel, the claimed catheter is inserted into the patient over a guidewire or guidance spiral, and blood is withdrawn, treated, and returned (see column 3, line 389 to column 4, line 11).

3. Claims 27, 28, 32, 34, and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,385,631 to Uthmann in view of US 6,758,836 to Zawacki.

In the specification and figures, Uthmann suggests the apparatus and method substantially as claimed by Applicant (see rejection above).

With regard to claim 27, Uthmann fails to disclose that the catheter is constructed of the claimed materials. Zawacki discloses a split tip dialysis catheter with slideable lumens wherein the catheter may be made of thermoplastics such as PTFE (see column 3, lines 24-33). It would have been obvious to one having ordinary skill in the art at the time the invention was made to use thermoplastics such as PTFE in the catheter

Art Unit: 3761

disclosed by Sorenson, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. See MPEP § 2144.07.

With regard to claim 28, Uthmann fails to disclose that the catheter comprises the claimed reinforcing materials. Zawacki discloses that reinforcing substances to reduce kinking may be used in the construction of the catheter, including wire (which is a metal formed as a flexible thread), which meets applicant's claim drawn to a metal (see column 4, lines 34-38). Therefore, it would have been obvious to add metal as disclosed by Zawacki to the catheter disclosed by Uthmann in order to reinforce the catheter structure, as taught by Zawacki.

With regard to claim 32, Uthmann suggests the method substantially as claimed by Applicant with the exception of deploying the catheter in the claimed location. However, Zawacki specifically discloses that the catheter may be introduced so that the catheter lies at the junction of the superior vena cava and the right atrium and that the position of the inner and outer lumens may be adjusted to provide for the correct location of the lumens within the vasculature (see column 3, lines 7-67). Therefore, it would have been obvious to place the lumens of the catheter disclosed by Zawacki in the locations claimed by applicant, since Zawacki suggests such positioning and teaches that the catheter is adjustable.

With regard to claim 34, Uthmann discloses a hub, but does not specifically teach that the catheters are replaceable. Zawacki discloses that the catheter assembly 10 comprises a hollow hub 40 that connects to the assembly (see FIG 1, column 3, lines

48-67). Zawacki further discloses that the inner lumen—which may act as either the venous lumen or arterial lumen, depending on the operation of the catheter (see column 4, lines 5-18)—is removable and replaceable (see column 1, lines 61-67).

With regard to claim 35, Uthmann fails to disclose the exact location of the insertion point. Zawacki discloses that the catheter may be inserted into one of the large central veins, which may include a jugular or subclavian vein (see column 2 line 65 to column 3, line 22).

4. Claim 26 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,385,631 to Uthmann in view of US 6,595,966 to Davey et al.

In the specification and figures, Uthmann suggests the device substantially as claimed by applicant (see rejection above) with the exception of a therapeutic agent.

With regard to claim 26, Davey discloses that a surface of the conduit may be treated with heparin, an anticoagulant, in order to prohibit deposit of materials on the surface of the conduit (see column 2, lines 25-30). Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to provide the catheter suggested by the prior art with a therapeutic agent such as an anticoagulant as disclosed by Davey in order to prevent deposit of materials on the surface of the conduit, as taught by Davey.

### ***Response to Arguments***

5. Applicant's arguments, filed 9/22/08, with respect to the rejection(s) of claim(s) under Sorenson and Zawacki have been fully considered and are persuasive.

Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Uthmann and Zawacki, as presented above.

6. Applicant argues that Sorenson discloses with great detail the attachment of the lumens to the hub with a bushing, making them not readily removable without great alteration. The Examiner agrees, and the rejection has been withdrawn.

### ***Conclusion***

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.



Any inquiry concerning this communication or earlier communications from the examiner should be directed to LESLIE R. DEAK whose telephone number is (571)272-4943. The examiner can normally be reached on Monday - Friday, 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on 571-272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leslie R. Deak/  
Primary Examiner  
Art Unit 3761  
10 December 2008